Shopping Cart
- Remove All
Your shopping cart is currently empty
MRS-1191 is an effective and selective A3 adenosine receptor antagonist (KB: 92 nM, a Ki: 31.4 nM for human A3 receptor and an IC50: 120 nM for CHO cells).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $670 | 6-8 weeks | |
| 50 mg | $871 | 6-8 weeks | |
| 100 mg | $1,490 | 6-8 weeks |
| Description | MRS-1191 is an effective and selective A3 adenosine receptor antagonist (KB: 92 nM, a Ki: 31.4 nM for human A3 receptor and an IC50: 120 nM for CHO cells). |
| Targets&IC50 | A3 receptor (human):(ki)31.4 nM |
| In vitro | MRS-1191 is found to be competitive in saturation binding studies using the agonist radioligand [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)adenosine-5'-N-methylbromide) at cloned human brain A3 receptor expressed in HEK-293 cells. The effects of putative A3 adenosine receptor antagonist of MRS-1191 is characterized in receptor binding and functional assays. MRS-1191 with a KB value of 92 nM, proves to be highly selective for human A3 receptor vs human A1 receptor-mediated effects on adenylate cyclase . |
| Molecular Weight | 477.55 |
| Formula | C31H27NO4 |
| Cas No. | 185222-90-6 |
| Relative Density. | 1.23 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (523.51 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.